Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared on X about a recent paper by Maurice Pérol:
“TRUST: Taletrectinib in ROS1+ NSCLC
TKI-naïve/pretreated: ORR 88.8/55.8%, Intracranial-ORR 76.5/65.6%, mPFS 45.6/9.7mo.”
“Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST.”
Authors: Maurice Pérol, Wei Li, Nathan A. Pennell, Geoffrey Liu, Yuichiro Ohe, Filippo De Braud, Misako Nagasaka, Enriqueta Felip, Anwen Xiong, Yongchang Zhang, Huijie Fan, Xicheng Wang, Shuanglian Li, Rose K. Lai, Feiwu Ran, Xianyu Zhang, Wenfeng Chen, Lyudmila Bazhenova, Caicun Zhou.
